cp wire

CP Wire Articles

Trajenta Meets Primary Endpoint in Cardiovascular Trial
  • Trajenta demonstrated cardiovascular safety in adults with type 2 diabetes and high vascular risk, with no need for dose adjustments regardless of kidney function
  • The study included... read more
Thu, 07/19/18 - 09:31 am
FDA Approves First Cancer Drug Under New Real Time Review Program
  • Kisqali approved under Real Time Oncology Review Program
  • One of two new programs intended to make the development of cancer drugs more effecient
  • Approval came less than one... read more
Wed, 07/18/18 - 01:20 pm
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
  • Observed responses to date show overall tumor reduction ranged from 60% to greater than 90%
  • Company is expanding trial cohort up to 30 additional patients
  • CLR 131 has orphan... read more
Wed, 07/18/18 - 09:58 am
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
  • TAK-935/OV935 is a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase
  • TAK-935/OV935 may potentially treat rare epilepsies by inhibiting CH24H to decrease 24HC levels... read more
Wed, 07/18/18 - 09:43 am
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
  • PDUFA target date is 1/18/19
  • Sacituzumab govitecan is an antibody drug conjugate (ADC)
  • If appproved it would be the first ADC approved for mTNBC
  • Company has another... read more
Wed, 07/18/18 - 09:27 am

Pages